Mani Arsalan

Mani Arsalan

Auto-generated profile, based on publicly available information

Mani Arsalan

Department of Cardiac Surgery, University Hospital of the Goethe University, Frankfurt/Main, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2016 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
MAMani Arsalan
Mani Arsalan
TWThomas Walther
Thomas Walther

17 November 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CHChristian W. Hamm
Christian W. Hamm
MAMani Arsalan
Mani Arsalan
MMMichael J. Mack
Michael J. Mack
Since the introduction of transcatheter aortic valve implantation (TAVI) into clinical practice, the treatment of aortic stenosis has changed dramatically. In the past, medical therapy with or without balloon aortic valvuloplasty was the only option for inoperable patients. More recently, TAVI has become the treatment of choice for these patients and the preferred alternative for high-risk operable patients. Surgical aortic valve replacement (SAVR) currently remains the gold standard for patients at low or intermediate operative risk. As randomized trials have demonstrated comparable results between TAVI and SAVR in the high-risk population, there is now a clear trend towards performing TAVI even in intermediate-risk patients while awaiting the results of randomized trials in that population. Nevertheless, there are still questions regarding TAVI involving paravalvular leak (PVL), stroke, pacemaker requirements, and durability that remain to be more definitively answered before TAVI can routinely be performed in a broader, lower risk population. Improvements in patient selection, imaging, and second and third generation devices have decreased the incidence of PVLs and vascular complications that followed the earliest TAVI procedures, but the rates of perioperative stroke and permanent pacemaker implantation must still be addressed. Furthermore, the long-term durability of TAVI devices and a role for post-procedure antithrombotic management remain unanswered. Until these questions are more clearly answered, it is the Heart Team's task to determine the optimal treatment for each patient based on risk scores, frailty metrics, comorbidities, patient preference, and potential for improvement in quality of life.

10 September 2015 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MAMani Arsalan
Mani Arsalan
TWThomas Walther
Thomas Walther
RSRobert L. Smith
Robert L. Smith
PGPaul A. Grayburn
Paul A. Grayburn
Tricuspid regurgitation (TR) is the most common lesion of the tricuspid valve (TV). Mild TR is common and usually is benign. However, moderate or severe TR can lead to irreversible myocardial damage and adverse outcomes. Despite these findings, few patients with significant TR undergo surgery. The treatment of functional (secondary) TR in particular remains controversial because of high rates of residual or recurrent TR and poor outcomes following surgical intervention. Traditional teaching that functional TR resolves on its own if the underlying disease is successfully treated has proven to be incorrect. This review aims to clarify management of TR by describing the anatomy, pathophysiology, diagnosis, and treatment of TR, including the eventual possibility of percutaneous TV therapy.

1 March 2016 in JACC
Verified
Journal Article
Closed access
MAMani Arsalan
Mani Arsalan
MSMolly Szerlip
Molly Szerlip
SVSreekanth Vemulapalli
Sreekanth Vemulapalli
EHElizabeth M. Holper
Elizabeth M. Holper
SASuzanne V. Arnold
Suzanne V. Arnold
MMMichael J. Mack
Michael J. Mack

1 January 2018 in EuroIntervention
Verified
Journal Article
Closed access
MAMani Arsalan
Mani Arsalan
WMWeferling Maren
Weferling Maren
FHFlorian Hecker
Florian Hecker
GFGiovanni Filardo
Giovanni Filardo
WKWon-Keun Kim
Won-Keun Kim
TWThomas Walther
Thomas Walther
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

9 August 2017 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
WKWon-Keun Kim
Won-Keun Kim
JBJohannes Blumenstein
Johannes Blumenstein
CLChristoph Liebetrau
Christoph Liebetrau
ARAndreas Rolf
Andreas Rolf
LGLuise Gaede
Luise Gaede
HMHelge Möllmann
Helge Möllmann